NICE
Price concession helps change NICE’s mind on Simponi
May 13, 2011Sales and Marketing NICE, Simponi, TNF, merck sharp and dohme
NICE has provisionally recommended Merck Sharp & Dohme’s Simponi for rheumatoid arthritis alongside other drugs in the TNF inhibitor class. …
Digital Pharma: NICE puts guidance into online pathways
May 11, 2011Sales and Marketing Digital Pharma blog, NICE
NICE has launched a new online tool that groups its guidance into user-friendly flowcharts to show care pathways. NICE Pathways …
‘Weak’ evidence leads to NICE no for three leukaemia drugs
May 6, 2011Sales and Marketing Glivec, NICE, Sprycel, Tasigna
NICE has not recommended three major drugs for the rare blood cancer chronic myeloid leukaemia. In draft guidance on treating …
NICE gives final no to PharmaMar’s Yondelis
April 27, 2011Sales and Marketing NICE, PharmaMar, Yondelis, ovarian cancer
A lack of evidence and an unconvincing patient access scheme has seen PharmaMar fail to win NICE backing for its …
NICE unimpressed with Novartis’ patient access scheme
April 19, 2011Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis
Novartis has been dealt a blow by NICE after the cost-effectiveness body finally refused to recommend, on appeal, its kidney …
GPs asked to squeeze drugs bill
April 14, 2011Sales and Marketing AZ, GPs, NHS, NICE, prescribing
GPs are being asked not to prescribe NICE-approved drugs in order to cut costs.In the last year more than half …
NICE rejects PharmaMar’s ovarian cancer drug Yondelis
March 14, 2011Sales and Marketing Cancer, NICE, PharmaMar, Trabectedin, Yondelis, ovarian cancer
NICE has rejected PharmaMar’s ovarian cancer drug in final draft guidance due to a lack of ‘robust’ data. Yondelis (trabectedin) …
NICE rejects Lucentis for diabetic oedema
March 4, 2011Sales and Marketing Lucentis, NICE, Novartis, VEGF, Vascular Endothelial Growth Factor, diabetic oedema, raibizumab
NICE’s draft guidance has not recommended Lucentis for diabetic oedema after ‘faulty analysis’ from manufacturer Novartis was found not to …
NICE yes for Votrient, no to Avastin
February 23, 2011Sales and Marketing Cancer, GSK, GlaxoSmithKline, Kidney cancer, NICE, Roche, avastin, bevacizumab, breast cancer
NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient on the same day it gave a final negative decision to Roche’s …
Value-based pricing will not harm industry, says NICE chief
February 18, 2011Sales and Marketing Health Select Committee, Health and Social Care Bill, NHS reform, NICE, Sir Andrew Dillon, value-based pricing
NICE’s chief executive Sir Andrew Dillon says he believes plans to introduce value-based pricing of medicines will not have a …
Vidaza patient access scheme sways NICE
February 17, 2011Sales and Marketing Celgene, NICE, Vidaza
Celgene’s Vidaza has been recommended by NICE in final draft guidance issued today. Vidaza (azacitidine) is recommended as a treatment …
Early diagnosis key to UK cancer ambition
February 8, 2011Cancer, NHS, NICE
A series of quality standards on cancer care is to be drawn up by NICE as part of a new …
Decision on osteoporosis drug Protelos unchanged, says NICE
January 27, 2011Sales and Marketing NICE, Protelos, Servier, osteoporotic fractures, strontium ranelate
NICE has published updated final guidance on preventing osteoporotic fractures following a reconsideration of the use of Servier’s Protelos. The …
NICE decides to back Abilify in schizophrenia
January 27, 2011Sales and Marketing Abilify, BMS, Bristol-Myers Squibb, NICE, Otsuka, aripiprazole, schizophrenia
NICE has changed its mind over Bristol-Myers Squibb’s and Otsuka Pharmaceuticals Abilify, deciding to recommend the drug as a schizophrenia …
